Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2007-02-20
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C546S209000, C548S200000
Reexamination Certificate
active
10787905
ABSTRACT:
Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I:As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.
REFERENCES:
patent: 5795876 (1998-08-01), Wright et al.
patent: 6069163 (2000-05-01), Delaszlo
patent: 6306887 (2001-10-01), Chupak et al.
patent: 6479519 (2002-11-01), Astles et al.
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 98/04913 (1998-02-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 98/53818 (1998-12-01), None
patent: WO 99/20272 (1999-04-01), None
patent: WO 99/23063 (1999-05-01), None
patent: WO 99/54321 (1999-10-01), None
Singh et al., Immune therapy in inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, pp. 1558-1569, 2001.
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21stCentury, Eur. J. Surg. Suppl 582, pp. 90-98, 1998.
Agrez et al., The alphavbeta6 Integrin induces Gelatinase B Secretion in colon cancer cells, Int. J. Cancer, 81, pp. 90-97, 1999.
Nip et al., The role of the integrin vitronectin receptor, alphavbeta3 in melanoma metastasis, Cancer and Metastasis Reviews, 14, pp. 241-252, 1995.
Bremner et al., Therapy of Crohn's Disease in childhood, Expert Opin. Pharmacother. 3(7):809-825, 2002.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Tarkowski et al., PubMed Abstract (Int Arch Allergy Immunol. 121(1):25-33), Jan. 2000.
Birner et al., Medline Abstract (European Journal of Immunology, vol. 29, Issue 4, pp. 1094-1100) Apr. 1999.
Lobb et al., Medline Abstract (Expert Opinion on Investigational Drugs, vol. 8, Issue 7, pp. 935-945) Jul. 1999.
Springer, Timothy A., “On a Roll with Cell Adhesion Molecules,”The Scientist, pp. 10, 13 (Aug. 1998).
Springer, Timothy A., “Adhesion Receptors of the Immune System,”Nature, 346:425-34 (Aug. 1990).
Baldwin John J.
Chiba Jun
Machinaga Nobuo
McDonald Edward
Moriarty Kevin Joseph
Daiichi Pharmaceutical Co. Ltd.
Heslin Rothenberg Farley & & Mesiti P.C.
Pharmacopeia Drug Discovery Inc.
Rao Deepak
LandOfFree
VLA-4 inhibitor compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VLA-4 inhibitor compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VLA-4 inhibitor compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853083